Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 169 people enrolled
- Started
- 2 Jun 2022
- Ended
- 7 Jan 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Nicotine Replacement
- Questionnaire Administration
- Electronic Cigarette
- Record updated
- 28 January 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 21 years or older
- Reports being a daily or non-daily smoker (any self-reported smoking in the past 30 days)
- Have an address where he/she can receive mail
- Able to follow verbal and written instructions in English and complete all aspects of the study as determined by PI
- Willing to have urine biospecimen samples taken, either in-home and returning them by mail, or in-person at an approved collection site
- Willing to use tobacco-flavored study electronic cigarettes
- Agrees to comply with all MD Anderson institutional policies related to COVID-19 screening prior to any in-person research visit
- The individual agrees to not engage in study procedures or interactions with study personnel while operating a vehicle
Who cannot take part
- Being pregnant, engaging in breast-feeding, or being of childbearing potential and engaging in sexual activity that could lead to pregnancy and is not protected by a medically acceptable, effective method of birth control while enrolled in the study, as determined by self-report. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use
- Uncontrolled or unstable medical condition (e.g., uncontrolled hypertension, angina, diabetes)
- Individuals who report depressive symptoms in the moderately severe or severe range on the PHQ-9 (scores of 15 or above) or who report current suicidal ideation on the PHQ-9
- Evidence of cognitive deficits or instability that would preclude reliable study participation
- Considered by the investigator to be an unsuitable or unstable candidate (including but not limited to the following situation: unwilling or unable to comply with study procedures)
- Individuals who reside in an area that is outside of our shipping company's area of operation or in a jurisdiction outside of our medical staff's licensure (if unable to attend in-person clinic visits) AND who decline or are unable to come in to clinic to provide necessary samples and/or collect study products
Where in United States
- M D Anderson Cancer CenterHouston, United States
About the trial
What the trial wants to find out
This early phase I trial studies potential differences between men and women when switching from the use of combustible cigarettes to the National Institute on Drug Abuse's Standard Research E-Cigarette (SREC). Studying the differences between men and women may increase understanding about the effects of switching from smoking regular cigarettes to electronic cigarettes.
The 2 groups in the trial
- E-Cig placebo dose followed by E-Cig nicotine doseTreatment being tested
Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
Treatment: Nicotine Replacement, Questionnaire Administration, and Electronic Cigarette
- E-Cig nicotine dose followed by E-Cig placebo doseTreatment being tested
Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
Treatment: Nicotine Replacement, Questionnaire Administration, and Electronic Cigarette
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Gender Differences in Standardized Research E-Cigarette (SREC) Product Use, Acceptability, Reinforcement, and Nicotine Dependence Symptoms
- Publications
- Standardized research electronic cigarette acceptability among adult men and women who smoke combustible cigarettes.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2025
- Record updated
- 28 January 2026